Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Martin_Shkreli
|
| gptkbp:controversy |
2015 Daraprim price hike
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:foundedBy |
gptkb:Martin_Shkreli
|
| gptkbp:foundedYear |
2015
|
| gptkbp:headquartersLocation |
gptkb:New_York_City
|
| https://www.w3.org/2000/01/rdf-schema#label |
Turing Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableFor |
acquisition and price increase of Daraprim
|
| gptkbp:product |
gptkb:Daraprim
|
| gptkbp:renamed |
gptkb:Vyera_Pharmaceuticals
|
| gptkbp:website |
https://www.vyera.com/
|
| gptkbp:bfsParent |
gptkb:Martin_Shkreli
|
| gptkbp:bfsLayer |
6
|